{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:10:52Z","timestamp":1793250652902,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["CIGE 2023\/200"],"award-info":[{"award-number":["CIGE 2023\/200"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aims to evaluate differences in adiposopathy and specific inflammatory biomarkers between type 2 diabetes mellitus (T2DM) and non-T2DM patients across various stages of chronic kidney disease (CKD). In addition, it explores potential pathways through which sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) impact renal outcomes via adipose tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      An observational prospective study was conducted on 143 CKD patients divided into 2 groups: SGLT2i cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931) and standard-of-care (SoC) cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009112). Clinical and analytical data were collected upon recruitment (T0) as well as after 8 months of follow-up (T8).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At T0, patients under the SGLT2i group showed higher significance for cardiovascular upload versus those in SoC treatment, as well as higher values across several inflammation parameters (IL-6, TNF-\u03b1, ferritin). At T8, renal function improved in the SGLT2i group in relation to the SoC, accompanied by a decrease in most inflammatory and adiposopathy biomarkers, mainly leptin. Notably, dapagliflozin use (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920) was associated with significantly reduced leptin levels and stabilization of TNF-\u03b1 concentrations vs. SoC at T8.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2i treatment, and particularly dapagliflozin, modulates both adiposopathy and systemic inflammation while slowing down renal function loss, demonstrating benefits for CKD patients regardless of diabetes status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-025-04965-6","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T07:54:49Z","timestamp":1765958089000},"page":"2721-2730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients"],"prefix":"10.1007","volume":"58","author":[{"given":"Ana","family":"Checa-Ros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owahabanun Joshua","family":"Okojie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelia","family":"Steib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bellasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Salvador-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"D\u2019Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"5","key":"4965_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","volume":"96","author":"KJ Jager","year":"2019","unstructured":"Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C (2019) A single number for advocacy and communication\u2014worldwide more than 850\u00a0million individuals have kidney diseases. Kidney Int 96(5):1048\u20131050. https:\/\/doi.org\/10.1016\/j.kint.2019.07.012","journal-title":"Kidney Int"},{"issue":"11","key":"4965_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N (2021) Cardiovascular disease in chronic kidney disease. Circulation 143(11):1157\u20131172. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050686","journal-title":"Circulation"},{"issue":"9","key":"4965_CR3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","volume":"18","author":"GM London","year":"2003","unstructured":"London GM (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18(9):1731\u20131740. https:\/\/doi.org\/10.1093\/ndt\/gfg414","journal-title":"Nephrol Dial Transplant"},{"key":"4965_CR4","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/ki.2008.516","volume":"74","author":"V Cachofeiro","year":"2008","unstructured":"Cachofeiro V, Goicochea M, de Vinuesa SG, Oubi\u00f1a P, Lahera V, Lu\u00f1o J (2008) Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int 74:S4\u2013S9. https:\/\/doi.org\/10.1038\/ki.2008.516","journal-title":"Kidney Int"},{"issue":"11","key":"4965_CR5","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1161\/CIRCRESAHA.115.306885","volume":"118","author":"JJ Fuster","year":"2016","unstructured":"Fuster JJ, Ouchi N, Gokce N, Walsh K (2016) Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res 118(11):1786\u20131807. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306885","journal-title":"Circ Res"},{"issue":"5","key":"4965_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3892\/etm.2021.9969","volume":"21","author":"D Miricescu","year":"2021","unstructured":"Miricescu D, Balan D, Tulin A et al (2021) Impact of adipose tissue in chronic kidney disease development (Review). Exp Ther Med 21(5):539. https:\/\/doi.org\/10.3892\/etm.2021.9969","journal-title":"Exp Ther Med"},{"issue":"21","key":"4965_CR7","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.3390\/healthcare11212831","volume":"11","author":"L D\u2019Marco","year":"2023","unstructured":"D\u2019Marco L, Checa-Ros A (2023) Exploring the link between cardiorenal and metabolic diseases. Healthcare 11(21):2831. https:\/\/doi.org\/10.3390\/healthcare11212831","journal-title":"Healthcare"},{"issue":"1","key":"4965_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-024-01325-9","volume":"16","author":"R Zhang","year":"2024","unstructured":"Zhang R, Xie Q, Lu X, Fan R, Tong N (2024) Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. Diabetol Metab Syndr 16(1):99. https:\/\/doi.org\/10.1186\/s13098-024-01325-9","journal-title":"Diabetol Metab Syndr"},{"issue":"12","key":"4965_CR9","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45(12):3075\u20133090. https:\/\/doi.org\/10.2337\/dci22-0027","journal-title":"Diabetes Care"},{"issue":"4","key":"4965_CR10","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ et al (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"12","key":"4965_CR11","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani LH et al (2019) Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care 42(12):2272\u20132281. https:\/\/doi.org\/10.2337\/dc19-0883","journal-title":"Diabetes Care"},{"issue":"6","key":"4965_CR12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/dom.13206","volume":"20","author":"SA Jabbour","year":"2018","unstructured":"Jabbour SA, Fr\u00edas JP, Guja C, Hardy E, Ahmed A, \u00d6hman P (2018) Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION\u20108 study. Diabetes Obes Metab 20(6):1515\u20131519. https:\/\/doi.org\/10.1111\/dom.13206","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"4965_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-015-0307-x","volume":"55","author":"E Hoeben","year":"2016","unstructured":"Hoeben E, De Winter W, Neyens M, Devineni D, Vermeulen A, Dunne A (2016) Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 55(2):209\u2013223. https:\/\/doi.org\/10.1007\/s40262-015-0307-x","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"4965_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G et al (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124(2):509\u2013514. https:\/\/doi.org\/10.1172\/JCI70704","journal-title":"J Clin Invest"},{"issue":"21","key":"4965_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"issue":"4","key":"4965_CR16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85(4):962\u2013971. https:\/\/doi.org\/10.1038\/ki.2013.356","journal-title":"Kidney Int"},{"issue":"3","key":"4965_CR17","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J et al (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97(3):1020\u20131031. https:\/\/doi.org\/10.1210\/jc.2011-2260","journal-title":"J Clin Endocrinol Metab"},{"key":"4965_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.381","author":"P Hanson","year":"2022","unstructured":"Hanson P, Randeva H, Cuthbertson DJ et al (2022) The DAPA\u2010DIET study: metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with type 2 diabetes mellitus and obesity\u2014a longitudinal cohort study. Endocrinology, Diabetes & Metabolism. https:\/\/doi.org\/10.1002\/edm2.381","journal-title":"Endocrinology, Diabetes & Metabolism"},{"issue":"4","key":"4965_CR19","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/ejhf.3221","volume":"26","author":"N Sattar","year":"2024","unstructured":"Sattar N, Butler J, Lee MMY et al (2024) Body mass index and cardiorenal outcomes in the EMPEROR\u2010Preserved trial: principal findings and meta\u2010analysis with the DELIVER trial. Eur J Heart Fail 26(4):900\u2013909. https:\/\/doi.org\/10.1002\/ejhf.3221","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"4965_CR20","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"7","key":"4965_CR21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR (2016) Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39(7):1115\u20131122. https:\/\/doi.org\/10.2337\/dc16-0542","journal-title":"Diabetes Care"},{"issue":"7","key":"4965_CR22","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/dom.15586","volume":"26","author":"L Buttice","year":"2024","unstructured":"Buttice L, Ghani M, Suthakar J et al (2024) The effect of sodium\u2010glucose cotransporter\u20102 inhibitors on inflammatory biomarkers: a meta\u2010analysis of randomized controlled trials. Diabetes Obes Metab 26(7):2706\u20132721. https:\/\/doi.org\/10.1111\/dom.15586","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"4965_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13335","volume":"73","author":"Y Aso","year":"2019","unstructured":"Aso Y, Kato K, Sakurai S et al (2019) Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase\u20104 in patients with type 2 diabetes and non\u2010alcoholic fatty liver disease. Int J Clin Pract 73(5):e13335. https:\/\/doi.org\/10.1111\/ijcp.13335","journal-title":"Int J Clin Pract"},{"issue":"20","key":"4965_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205237","volume":"20","author":"T Jojima","year":"2019","unstructured":"Jojima T, Wakamatsu S, Kase M et al (2019) The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma. Int J Mol Sci 20(20):5237. https:\/\/doi.org\/10.3390\/ijms20205237","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4965_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jphs.2021.09.009","volume":"148","author":"D Sato","year":"2022","unstructured":"Sato D, Nakamura T, Amarume J et al (2022) Effects of dapagliflozin on peripheral sympathetic nerve activity in standard chow- and high-fat-fed rats after a glucose load. J Pharmacol Sci 148(1):86\u201392. https:\/\/doi.org\/10.1016\/j.jphs.2021.09.009","journal-title":"J Pharmacol Sci"},{"key":"4965_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"L Xu","year":"2017","unstructured":"Xu L, Nagata N, Nagashimada M et al (2017) SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine 20:137\u2013149. https:\/\/doi.org\/10.1016\/j.ebiom.2017.05.028","journal-title":"EBioMedicine"},{"key":"4965_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9032378","volume":"2021","author":"L D\u2019Marco","year":"2021","unstructured":"D\u2019Marco L, Morillo V, Gorriz JL et al (2021) SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence. J Diabetes Res 2021:1\u201317. https:\/\/doi.org\/10.1155\/2021\/9032378","journal-title":"J Diabetes Res"},{"issue":"16","key":"4965_CR28","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.18632\/aging.102175","volume":"11","author":"\u00c1 Garc\u00eda-Ropero","year":"2019","unstructured":"Garc\u00eda-Ropero \u00c1, Santos-Gallego CG, Badimon JJ (2019) The anti-inflammatory effects of SGLT inhibitors. Aging 11(16):5866\u20135867. https:\/\/doi.org\/10.18632\/aging.102175","journal-title":"Aging"},{"issue":"3","key":"4965_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA et al (2021) Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 77(3):243\u2013255. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.008","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"4965_CR30","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3390\/cells12121581","volume":"12","author":"SP Kadatane","year":"2023","unstructured":"Kadatane SP, Satariano M, Massey M, Mongan K, Raina R (2023) The role of inflammation in CKD. Cells 12(12):1581. https:\/\/doi.org\/10.3390\/cells12121581","journal-title":"Cells"},{"issue":"3","key":"4965_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000126926","volume":"26","author":"JJ Carrero","year":"2008","unstructured":"Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P (2008) Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 26(3):291\u2013299. https:\/\/doi.org\/10.1159\/000126926","journal-title":"Blood Purif"},{"issue":"1","key":"4965_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12882-019-1309-y","volume":"20","author":"S Peng","year":"2019","unstructured":"Peng S, He J, Huang J et al (2019) Self-management interventions for chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol 20(1):142. https:\/\/doi.org\/10.1186\/s12882-019-1309-y","journal-title":"BMC Nephrol"},{"issue":"15","key":"4965_CR33","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"4965_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2019.11.016","volume":"292","author":"M Couselo-Seijas","year":"2020","unstructured":"Couselo-Seijas M, Agra-Bermejo RM, Fern\u00e1ndez AL et al (2020) High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment. Atherosclerosis 292:60\u201369. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.11.016","journal-title":"Atherosclerosis"},{"issue":"4","key":"4965_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041670","volume":"26","author":"EY Rykova","year":"2025","unstructured":"Rykova EY, Klimontov VV, Shmakova E, Korbut AI, Merkulova TI, Kzhyshkowska J (2025) Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages. Int J Mol Sci 26(4):1670. https:\/\/doi.org\/10.3390\/ijms26041670","journal-title":"Int J Mol Sci"},{"key":"4965_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.745058","author":"L Xu","year":"2021","unstructured":"Xu L, Xu C, Liu X et al (2021) Empagliflozin induces white adipocyte browning and modulates mitochondrial dynamics in KK Cg-Ay\/J mice and mouse adipocytes. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2021.745058","journal-title":"Front Physiol"},{"issue":"1","key":"4965_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40360-024-00747-5","volume":"25","author":"L Xiang","year":"2024","unstructured":"Xiang L, Liu M, Xiang G et al (2024) Dapagliflozin promotes white adipose tissue browning though regulating angiogenesis in high fat induced obese mice. BMC Pharmacol Toxicol 25(1):26. https:\/\/doi.org\/10.1186\/s40360-024-00747-5","journal-title":"BMC Pharmacol Toxicol"},{"issue":"9896","key":"4965_CR38","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941\u2013950. https:\/\/doi.org\/10.1016\/S0140-6736(13)60683-2","journal-title":"Lancet"},{"issue":"11","key":"4965_CR39","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/biomedicines8110514","volume":"8","author":"JR Matthews","year":"2020","unstructured":"Matthews JR, Herat LY, Magno AL, Gorman S, Schlaich MP, Matthews VB (2020) SGLT2 inhibitor-induced sympathoexcitation in white adipose tissue: a novel mechanism for beiging. Biomedicines 8(11):514. https:\/\/doi.org\/10.3390\/biomedicines8110514","journal-title":"Biomedicines"},{"key":"4965_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117414","volume":"247","author":"D Wei","year":"2020","unstructured":"Wei D, Liao L, Wang H, Zhang W, Wang T, Xu Z (2020) Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPAR\u03b1 in vivo and in vitro. Life Sci 247:117414. https:\/\/doi.org\/10.1016\/j.lfs.2020.117414","journal-title":"Life Sci"},{"issue":"8","key":"4965_CR41","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/cells10082150","volume":"10","author":"W Masson","year":"2021","unstructured":"Masson W, Lavalle-Cobo A, Nogueira JP (2021) Effect of SGLT2-inhibitors on epicardial adipose tissue: a meta-analysis. Cells 10(8):2150. https:\/\/doi.org\/10.3390\/cells10082150","journal-title":"Cells"},{"issue":"24","key":"4965_CR42","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"issue":"2","key":"4965_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"issue":"9","key":"4965_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2025.03.009","volume":"10","author":"R Basdas","year":"2025","unstructured":"Basdas R, Mart\u00ednez-Cereijo JM, Fern\u00e1ndez \u00c1L et al (2025) Semaglutide modulates proinflammatory epicardial adipogenesis with paracrine effects on hiPSC-atrial cardiomyocytes. JACC: Basic to Translational Science 10(9):101277. https:\/\/doi.org\/10.1016\/j.jacbts.2025.03.009","journal-title":"JACC: Basic to Translational Science"},{"issue":"10","key":"4965_CR45","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/metabo14100554","volume":"14","author":"\u0141 Bu\u0142dak","year":"2024","unstructured":"Bu\u0142dak \u0141, Bo\u0142dys A, Skudrzyk E, Machnik G, Okopie\u0144 B (2024) Liraglutide therapy in obese patients alters macrophage phenotype and decreases their tumor necrosis factor alpha release and oxidative stress markers\u2014a pilot study. Metabolites 14(10):554. https:\/\/doi.org\/10.3390\/metabo14100554","journal-title":"Metabolites"},{"issue":"2","key":"4965_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.08.019","volume":"35","author":"G Iacobellis","year":"2025","unstructured":"Iacobellis G, Goldberger JJ, Lamelas J et al (2025) Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control. Nutr Metab Cardiovasc Dis 35(2):103726. https:\/\/doi.org\/10.1016\/j.numecd.2024.08.019","journal-title":"Nutr Metab Cardiovasc Dis"}],"updated-by":[{"DOI":"10.1007\/s11255-026-05028-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000}}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04965-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:28:14Z","timestamp":1787563694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04965-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4965"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04965-6","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The given and family names are corrected for all the author names in author group.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11255-026-05028-0","URL":"https:\/\/doi.org\/10.1007\/s11255-026-05028-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}